Mei Mei Hu
Founder bei VAXXINITY, INC.
Vermögen: 51 Mio $ am 31.03.2024
Profil
Mei Mei Hu, Gründer von Vaxxinity, Inc. ist derzeit Präsident, Chief Executive Officer und Direktor dieses Unternehmens. Herr Hu ist auch Mitglied des Vorstands von United BioPharma, Inc. Er erwarb einen Bachelor-Abschluss an der University of Pennsylvania und einen Master-Abschluss an der Harvard Law School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VAXXINITY INC CLASS A
57,67% | 31.12.2023 | 65 096 861 ( 57,67% ) | 47 Mio $ | 31.03.2024 |
VAXXINITY INC CLASS B
39,78% | 31.12.2023 | 5 518 961 ( 39,78% ) | 4 Mio $ | 31.03.2024 |
Aktive Positionen von Mei Mei Hu
| Unternehmen | Position | Beginn |
|---|---|---|
| VAXXINITY, INC. | Founder | 01.01.2014 |
| UNITED BIOPHARMA INC | Director/Board Member | 01.03.2020 |
Covaxx, Inc.
 Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Chief Executive Officer | 01.03.2020 |
Ehemalige bekannte Positionen von Mei Mei Hu
| Unternehmen | Position | Ende |
|---|---|---|
| Shen Lian Biotechnology Co. Ltd. | Director/Board Member | 01.01.2014 |
| United Neuroscience LLC | Director/Board Member | - |
Ausbildung von Mei Mei Hu
| University of Pennsylvania | Undergraduate Degree |
| Harvard Law School | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| VAXXINITY, INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
United BioPharma, Inc.
 United BioPharma, Inc. Pharmaceuticals: MajorHealth Technology United BioPharma, Inc. engages in the development, manufacture, and sale of monoclonal antibody drug. The company's business activities include the manufacture and sale of western drugs. Its products include trastumab, adalimumab, bevacizumab, rituximab, and omalizumab. The company was founded by Chang Yi Wang on September 30, 2013 and is headquartered in Hsinchu, Taiwan. | Health Technology |
Covaxx, Inc.
Covaxx, Inc. BiotechnologyHealth Technology Covaxx, Inc. is a vaccine development company that focuses on creating vaccines for COVID-19, neurological disorders such as Alzheimer's and Parkinson's diseases, as well as prevalent chronic disorders like migraine and hypercholesterolemia. The private company is based in Dallas, TX, with operations in other locations. Covaxx recently consolidated with United Neuroscience to form a new holding company called Vaxxinity, Inc. Vaxxinity's lead candidate in its pipeline is UB-612, a vaccine candidate to fight SARS-CoV-2. Additionally, Vaxxinity has deployed hundreds of thousands of SARS-CoV-2 ELISA tests, which have received FDA emergency use authorization (EUA). The company was founded in 2020 by Peter H. Diamandis, and the CEO is Mei Mei Hu. | Health Technology |
| United Neuroscience LLC | |
| Shen Lian Biotechnology Co. Ltd. |
